ERBB2 and breast cancer: Voduc et al[29] reported that 10-year LR was similar to RR in patients with HR−/HER2+ breast cancer (16% vs 14%), while 10-year LR was almost twice higher than RR in patients with HR+/HER2− breast cancer (8% vs 3%).